Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine.
Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine.
复制标题
DOI:
10.1038/s41586-021-03841-4
复制
发表时间:
2021-09
期刊:
影响因子:
64.8
通讯作者:
Hofmann M
中科院分区:
文献类型:
--
作者:
Oberhardt V;Luxenburger H;Kemming J;Schulien I;Ciminski K;Giese S;Csernalabics B;Lang-Meli J;Janowska I;Staniek J;Wild K;Basho K;Marinescu MS;Fuchs J;Topfstedt F;Janda A;Sogukpinar O;Hilger H;Stete K;Emmerich F;Bengsch B;Waller CF;Rieg S;Sagar;Boettler T;Zoldan K;Kochs G;Schwemmle M;Rizzi M;Thimme R;Neumann-Haefelin C;Hofmann M
SARS-CoV-2 spike mRNA vaccines mediate protection from severe disease as early as ten days after prime vaccination, when neutralizing antibodies are hardly detectable. Vaccine-induced CD8+ T cells may therefore be the main mediators of protection at this early stage. The details of their induction, comparison to natural infection, and association with other arms of vaccine-induced immunity remain, however, incompletely understood. Here we show on a single-epitope level that a stable and fully functional CD8+ T cell response is vigorously mobilized one week after prime vaccination with bnt162b2, when circulating CD4+ T cells and neutralizing antibodies are still weakly detectable. Boost vaccination induced a robust expansion that generated highly differentiated effector CD8+ T cells; however, neither the functional capacity nor the memory precursor T cell pool was affected. Compared with natural infection, vaccine-induced early memory T cells exhibited similar functional capacities but a different subset distribution. Our results indicate that CD8+ T cells are important effector cells, are expanded in the early protection window after prime vaccination, precede maturation of other effector arms of vaccine-induced immunity and are stably maintained after boost vaccination. Longitudinal analyses of SARS-CoV-2 mRNA vaccine-elicited epitope-specific CD8+ T cell responses shows that CD8+ T cells are rapidly induced after prime vaccination and stably maintained after boost vaccination.
登录
查看更多内容
DOI:
10.1056/nejmoa2034577
发表时间:
2020-12-31
期刊:
The New England journal of medicine
影响因子:
--
作者:
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者:
C4591001 Clinical Trial Group
影响因子:
32.4
作者:
Lederer K;Castaño D;Gómez Atria D;Oguin TH 3rd;Wang S;Manzoni TB;Muramatsu H;Hogan MJ;Amanat F;Cherubin P;Lundgreen KA;Tam YK;Fan SHY;Eisenlohr LC;Maillard I;Weissman D;Bates P;Krammer F;Sempowski GD;Pardi N;Locci M
通讯作者:
Locci M
DOI:
10.1056/nejmoa2035389
发表时间:
2021-02-04
期刊:
The New England journal of medicine
影响因子:
--
作者:
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者:
COVE Study Group
影响因子:
24.8
作者:
Goel RR;Apostolidis SA;Painter MM;Mathew D;Pattekar A;Kuthuru O;Gouma S;Hicks P;Meng W;Rosenfeld AM;Dysinger S;Lundgreen KA;Kuri-Cervantes L;Adamski S;Hicks A;Korte S;Oldridge DA;Baxter AE;Giles JR;Weirick ME;McAllister CM;Dougherty J;Long S;D'Andrea K;Hamilton JT;Betts MR;Luning Prak ET;Bates P;Hensley SE;Greenplate AR;Wherry EJ
通讯作者:
Wherry EJ
影响因子:
30.5
作者:
Kaech, SM;Ahmed, R
通讯作者:
Ahmed, R